BioMedNewsBreaks

WednesdayMar 26, 2025 10:33 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope

Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so far with no safety concerns, and the study is now enrolling patients into the highest dosing cohort. The trial has expanded to Northwestern University and Stanford University, and is supported by a $12 million grant from the California Institute for Regenerative Medicine. Calidi retains licensing…

Continue Reading

TuesdayMar 25, 2025 2:13 pm

BioMedNewsBreaks — Adageis Is Bringing AI to the Forefront of Value-Based Care

Adageis, a leading healthcare technology company, is at the forefront of an industry shift as providers increasingly prioritize specific, high-impact artificial intelligence (“AI”) applications that enhance patient care and financial performance. The company was featured in a recent article that discussed its innovative AI-driven solutions through its ProActive Care Platform, which offers practical applications that directly impact revenue generation and patient care. Adageis’ AI solutions stand distinct in providing key competencies in several areas including risk identification and early intervention, revenue tracking and forecasting, clinical decision support, administrative task automation, and continuous patient monitoring. Adageis’ platform demonstrates how AI can…

Continue Reading

TuesdayMar 25, 2025 10:43 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial 

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with other anthracyclines, and the safety profile remained favorable. The company plans to continue analysis and explore further development of Berubicin and its pipeline candidate TPI 287 for CNS malignancies.  To view the full press release,…

Continue Reading

TuesdayMar 25, 2025 9:58 am

BioMedNewsBreaks — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Hosts Investor Call Highlighting Actimab-A Clinical Progress and Expansion into Solid Tumors 

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, will hold an investor call today at 8:00 a.m. ET featuring Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin and principal investigator of the Actimab-A + CLAG-M trial for relapsed/refractory acute myeloid leukemia (r/r AML). Dr. Atallah will present updated clinical results, including long-term survival data and plans for a pivotal Phase 2/3 trial under Actinium's cooperative research and development agreement ("CRADA") with the National Cancer Institute. Actinium's management will also discuss the launch of its Actimab-A solid tumor program, which includes trials combining Actimab-A with…

Continue Reading

TuesdayMar 25, 2025 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the company as it continues to highlight progress across its therapeutic pipeline. The conference is hosted by JonesTrading with marketing support from B2i Digital, Inc. To view the full press release, visit https://ibn.fm/nW2zd About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned…

Continue Reading

TuesdayMar 25, 2025 9:20 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from roughly $60 million in non-dilutive funding and a pipeline that includes multiple orphan and fast-track designations, the company is preparing for potential regulatory approvals. IBN will amplify Soligenix’s message through its expansive media and investor network. To view the full article, visit https://ibn.fm/0jkfI About Soligenix…

Continue Reading

MondayMar 24, 2025 10:44 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data 

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, compared to a loss of $49.5 million in 2023. Revenue remained limited, but Clene highlighted regulatory progress and survival data supporting CNM-Au8, its gold nanocrystal suspension for ALS. The company expects to meet with the FDA in Q2 2025 to finalize analysis plans for biomarker data, with a potential accelerated NDA submission in the second half of 2025. Clene ended the year with $12.2 million in cash and expects to begin enrollment for its confirmatory Phase 3 RESTORE-ALS trial in…

Continue Reading

MondayMar 24, 2025 9:42 am

BioMedNewsBreaks — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Secures Actinium-225 Supply Agreement with Eckert & Ziegler to Support Expanding Pipeline 

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, announced a supply agreement with Eckert & Ziegler for Actinium-225 (Ac-225) to support development of its lead candidate Actimab-A and other radiotherapy programs. The agreement ensures access to high-quality Ac-225 for both U.S. and international clinical trials. Actimab-A, an Ac-225-based agent targeting CD33, is being advanced into pivotal Phase 2/3 trials for relapsed/refractory acute myeloid leukemia and early-stage studies in combination with checkpoint inhibitors for solid tumors including head and neck and non-small cell lung cancers. The partnership strengthens Actinium’s ability to scale development and meet global demand for targeted…

Continue Reading

FridayMar 21, 2025 2:31 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The company’s approach includes a systemic platform using extracellular enveloped viruses and an intratumoral platform utilizing stem cells to protect the therapy from the body’s immune system during administration. Calidi’s pipeline includes promising therapies such as RTNova,…

Continue Reading

FridayMar 21, 2025 12:34 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events this month, including the Q1 Virtual Investor Summit and the 37th Annual Roth Conference. At both events, Clene’s management discussed the latest achievements with CNM-Au8, a gold nanocrystal-based oral suspension that targets mitochondrial dysfunction and promotes neuronal health. The drug has shown promising results in…

Continue Reading